AI's Impact on the Drug Targeting Process - with Ramesh Durvasula of Lilly

episode

The AI in Business Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Can Toia Shut Herbie Down? Penrith's Vulnerable State & Moses' Lebanon Exit!| NRL Daily 47 min · 24 Sep 2026 · Triple M Rocks Footy NRL

Ask, Tell, Confess: I Can't Believe He CHEATED?! 31 min · 24 Sep 2026 · Dumb Blonde

NPR News: 09-23-2026 10PM EDT 4 min · 24 Sep 2026 · NPR News Now

10PM ET 09/23/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Xi in Washington, US-China Trade Truce Extended, More 8 min · 24 Sep 2026 · Bloomberg News Now

Whateley in a Snapshot | Thursday (24.09.26) 6 min · 24 Sep 2026 · Whateley

Report any issue

Source

Recorded07 Nov 2023

Publishertechemergence.libsyn.com ↗

Handlerec:6021070

Show notes

Today's guest is Ramesh Durvasula, Senior Vice President of R&D IT at Lilly. Ramesh joins us on the program today to discuss AI's impact on the drug targeting process, particularly in helping pharmaceutical leaders like Lilly better predict what potential drugs to invest in for bringing to market and when. With increased certainty in drug targeting, Ramesh explains how AI capabilities are driving clinical trials to be used as an alternative form of healthcare. Visit emerj.com/beg1 to learn more about the practical steps for AI deployment for non-technical professionals.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in